Bringing together talented scientists, experienced leaders and innovative entrepreneurs.

Learn More

Developing and commercializing innovative drugs to treat cancer and orphan diseases and protect healthy tissues.

Learn More

Building a robust pipeline of oncology and orphan drugs focused in multiple indications.

Learn More

Developing powerful drugs to protect from radiation.

Learn More


Product Portfolio

Our pipeline includes several novel clinical-stage drug candidates for cancer treatment and protection from lethal radiation.

View Our Product Portfolio

Lead Compounds

Our lead product candidates are entolimod (CBLB502), which we are developing for a biodefense indication and as an oncology drug, and Curaxin CBL0137, our lead oncology product candidate.

entolimod (CBLB502) Biodefense entolimod (CBLB502) Oncology CBL0137

Clinical Trials

We are aggressively pursuing development and commercialization of oncology drugs, orphan applications, and a radiation countermeasure.

Enrollment is open for our therapeutic clinical trials for various indications with oncology drug candidates in the pipeline.

Learn More About our Phase 1 oncology study with entolimod (CBLB502) Learn More About our Phase 1 oncology study with oral CBL0137 Learn More About our Phase 1 oncology study with i.v. CBL0137

Recent News

Read All News

You are now leaving this website. If you would like to continue, click Continue.